Amanda Valliant, MD
Nephrology · Wichita, KSNPI 1609004316
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $696 and has fallen 52.9% since, to $328 in 2025.
Across 126 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$453
- Medtronic$331
- Amgen$243
- Mozarc Medical US LLC$162
- Mallinckrodt Enterprises LLC$159
- OPKO Pharmaceuticals, LLC$132
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,73196%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 12 | $453 |
| Medtronic | 20 | $331 |
| Amgen(2 entities) | 9 | $243 |
| Mozarc Medical US LLC | 8 | $162 |
| Mallinckrodt Enterprises LLC | 4 | $159 |
| OPKO Pharmaceuticals, LLC | 9 | $132 |
| Ardelyx, Inc. | 6 | $114 |
| Vifor Pharma, Inc. | 6 | $113 |
| Baxter Healthcare | 1 | $106 |
| Aurinia Pharma U.S., Inc. | 6 | $105 |
| Scpharmaceuticals Inc. | 1 | $105 |
| Novartis | 4 | $103 |
| Fresenius USA Marketing, Inc. | 5 | $81 |
| AstraZeneca(2 entities) | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Novo Nordisk | 3 | $59 |
| ANI Pharmaceuticals, Inc. | 3 | $54 |
| Kyowa Kirin, Inc. | 3 | $53 |
| Boehringer Ingelheim | 2 | $44 |
| Pharmacosmos Therapeutics Inc. | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Akebia Therapeutics Inc | 3 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Calliditas Therapeutics US Inc. | 2 | $37 |
| GSK | 1 | $20 |
| Travere Therapeutics, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Shield Therapeutics Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,831 in reported general payments places this provider in the 70th percentile of 55 nephrology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 23 | $244,974 |
| FarxigaDapagliflozin Propanediol | 46 | $33,786 |
| JardianceEmpagliflozin | 31 | $30,744 |
| KerendiaFinerenone | 22 | $18,988 |
| AuryxiaFerric Citrate | 12 | $16,444 |
| EliquisApixaban | 14 | $13,397 |
| MyrbetriqMirabegron | 15 | $9,544 |
| Sevelamer Carbonate | 51 | $7,551 |
| Bumetanide | 123 | $3,444 |
| Potassium Citrate ErPotassium Citrate | 26 | $3,296 |
| Methenamine Hippurate | 40 | $3,211 |
| Calcitriol | 91 | $2,025 |
| Clonidine | 13 | $1,723 |
| Nifedipine ErNifedipine | 46 | $1,575 |
| Amlodipine Besylate | 199 | $1,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Crysvita | $53 | $244,97423 claims |
| AstraZenecaFarxiga | $69 | $33,78646 claims |
| Boehringer IngelheimJardiance | $44 | $30,74431 claims |
| BayerKerendia | $453 | $18,98822 claims |
| Akebia Therapeutics IncAuryxia | $39 | $16,44412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 55 nephrology providers in Kansas.
Other nephrology in Wichita
- Edgard WehbeWichita$49K
- Dennis RossWichita$12K
- Mohamad SandidWichita$6K
- Jany MoussaWichita$4K
- Ushasri ChallaWichita$3K
- Joseph MeouchyWichita$2K
- Michael GrantWichita$2K
- Lisa WeberWichita$2K
- Levi ShortWichita$1K
- Kenneth KovachWichita$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.